ReShape Lifesciences (RSLS) Competitors $2.49 +0.05 (+2.05%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.46 -0.03 (-1.16%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock RSLS vs. BIAF, ABT, ISRG, BSX, SYK, MDT, BDX, EW, IDXX, and RMDShould you be buying ReShape Lifesciences stock or one of its competitors? The main competitors of ReShape Lifesciences include bioAffinity Technologies (BIAF), Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Boston Scientific (BSX), Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), and ResMed (RMD). These companies are all part of the "medical" sector. ReShape Lifesciences vs. Its Competitors bioAffinity Technologies Abbott Laboratories Intuitive Surgical Boston Scientific Stryker Medtronic Becton, Dickinson and Company Edwards Lifesciences IDEXX Laboratories ResMed ReShape Lifesciences (NASDAQ:RSLS) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment. Which has more risk & volatility, RSLS or BIAF? ReShape Lifesciences has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, bioAffinity Technologies has a beta of 2.53, suggesting that its share price is 153% more volatile than the S&P 500. Is RSLS or BIAF more profitable? ReShape Lifesciences has a net margin of -48.26% compared to bioAffinity Technologies' net margin of -110.53%. ReShape Lifesciences' return on equity of -251.90% beat bioAffinity Technologies' return on equity.Company Net Margins Return on Equity Return on Assets ReShape Lifesciences-48.26% -251.90% -59.49% bioAffinity Technologies -110.53%-367.64%-154.15% Do analysts recommend RSLS or BIAF? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ReShape Lifesciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00bioAffinity Technologies 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders & institutionals have more ownership in RSLS or BIAF? 22.1% of ReShape Lifesciences shares are owned by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are owned by institutional investors. 0.0% of ReShape Lifesciences shares are owned by insiders. Comparatively, 16.9% of bioAffinity Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media favor RSLS or BIAF? In the previous week, bioAffinity Technologies had 1 more articles in the media than ReShape Lifesciences. MarketBeat recorded 1 mentions for bioAffinity Technologies and 0 mentions for ReShape Lifesciences. ReShape Lifesciences' average media sentiment score of 0.00 equaled bioAffinity Technologies'average media sentiment score. Company Overall Sentiment ReShape Lifesciences Neutral bioAffinity Technologies Neutral Which has better valuation and earnings, RSLS or BIAF? ReShape Lifesciences has higher earnings, but lower revenue than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than ReShape Lifesciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReShape Lifesciences$8.01M0.74-$7.13M-$193.23-0.01bioAffinity Technologies$9.36M0.89-$9.04M-$0.72-0.41 SummarybioAffinity Technologies beats ReShape Lifesciences on 7 of the 13 factors compared between the two stocks. Get ReShape Lifesciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RSLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RSLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RSLS vs. The Competition Export to ExcelMetricReShape LifesciencesMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.82M$6.70B$5.49B$9.54BDividend YieldN/A1.32%4.73%4.09%P/E Ratio-0.0120.9428.8623.83Price / Sales0.7454.12371.4866.02Price / CashN/A20.5035.4557.96Price / Book-0.294.468.275.54Net Income-$7.13M$174.54M$3.25B$259.28M7 Day Performance0.40%-5.27%-3.73%-4.68%1 Month Performance2.89%-3.94%4.29%4.36%1 Year Performance-99.06%8.26%25.87%17.89% ReShape Lifesciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RSLSReShape Lifesciences0.6707 of 5 stars$2.49+2.0%N/A-99.1%$5.82M$8.01M-0.0150BIAFbioAffinity Technologies0.4343 of 5 stars$0.34+0.6%N/A-87.7%$9.51M$9.36M-0.4710News CoveragePositive NewsABTAbbott Laboratories4.983 of 5 stars$126.28-0.2%$144.47+14.4%+15.6%$220.16B$41.95B15.82114,000Positive NewsISRGIntuitive Surgical4.7361 of 5 stars$493.95-0.4%$592.05+19.9%+7.1%$177.75B$9.15B68.8915,638Positive NewsInsider TradeBSXBoston Scientific4.5367 of 5 stars$105.84-0.3%$117.50+11.0%+40.2%$157.03B$16.75B63.0053,000Trending NewsInsider TradeSYKStryker4.9233 of 5 stars$400.43-0.8%$428.55+7.0%+13.6%$154.02B$22.60B54.1153,000Trending NewsEarnings ReportAnalyst ForecastGap DownMDTMedtronic4.5626 of 5 stars$91.99-1.0%$98.19+6.7%+11.0%$119.20B$33.54B25.4195,000Positive NewsBDXBecton, Dickinson and Company4.4465 of 5 stars$183.06-1.2%$219.22+19.8%-25.3%$53.11B$20.18B34.9474,000Positive NewsUpcoming EarningsEWEdwards Lifesciences4.4846 of 5 stars$78.46-1.9%$85.00+8.3%+28.2%$46.93B$5.44B11.2915,800Analyst UpgradeIDXXIDEXX Laboratories3.2896 of 5 stars$566.50+0.2%$557.88-1.5%+12.1%$45.45B$3.90B52.3611,000Positive NewsUpcoming EarningsRMDResMed4.392 of 5 stars$273.52-0.6%$263.00-3.8%+29.9%$40.35B$4.69B30.709,980Trending NewsEarnings ReportDividend IncreaseAnalyst ForecastGap Up Related Companies and Tools Related Companies BIAF Alternatives ABT Alternatives ISRG Alternatives BSX Alternatives SYK Alternatives MDT Alternatives BDX Alternatives EW Alternatives IDXX Alternatives RMD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RSLS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ReShape Lifesciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ReShape Lifesciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RSLS Stock Alerts